ES264510A1 - Metodo para la preparaciën de preparados de hierro de elevado poder de absorciën - Google Patents
Metodo para la preparaciën de preparados de hierro de elevado poder de absorciënInfo
- Publication number
- ES264510A1 ES264510A1 ES0264510A ES264510A ES264510A1 ES 264510 A1 ES264510 A1 ES 264510A1 ES 0264510 A ES0264510 A ES 0264510A ES 264510 A ES264510 A ES 264510A ES 264510 A1 ES264510 A1 ES 264510A1
- Authority
- ES
- Spain
- Prior art keywords
- ferrous
- succinate
- preparations
- iron
- aneurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940082629 iron antianemic preparations Drugs 0.000 title abstract 2
- -1 ferrous compound Chemical class 0.000 abstract 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical group O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 239000011782 vitamin Substances 0.000 abstract 2
- 235000013343 vitamin Nutrition 0.000 abstract 2
- 229940088594 vitamin Drugs 0.000 abstract 2
- 229930003231 vitamin Natural products 0.000 abstract 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- MSZSGKIGWIVVOP-UHFFFAOYSA-N carboxymethylazanium;hydrogen sulfate Chemical compound NCC(O)=O.OS(O)(=O)=O MSZSGKIGWIVVOP-UHFFFAOYSA-N 0.000 abstract 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 1
- 239000000686 essence Substances 0.000 abstract 1
- 229960002089 ferrous chloride Drugs 0.000 abstract 1
- 235000013924 ferrous gluconate Nutrition 0.000 abstract 1
- 229960001645 ferrous gluconate Drugs 0.000 abstract 1
- 239000004222 ferrous gluconate Substances 0.000 abstract 1
- 235000003891 ferrous sulphate Nutrition 0.000 abstract 1
- 239000011790 ferrous sulphate Substances 0.000 abstract 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 abstract 1
- 159000000014 iron salts Chemical class 0.000 abstract 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940055726 pantothenic acid Drugs 0.000 abstract 1
- 235000019161 pantothenic acid Nutrition 0.000 abstract 1
- 239000011713 pantothenic acid Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 abstract 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 abstract 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 235000019192 riboflavin Nutrition 0.000 abstract 1
- 239000002151 riboflavin Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229940014800 succinic anhydride Drugs 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE101260 | 1960-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES264510A1 true ES264510A1 (es) | 1961-10-01 |
Family
ID=20257439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES0264510A Expired ES264510A1 (es) | 1960-02-03 | 1961-01-31 | Metodo para la preparaciën de preparados de hierro de elevado poder de absorciën |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE599466A (en:Method) |
| ES (1) | ES264510A1 (en:Method) |
| FR (1) | FR904M (en:Method) |
| GB (1) | GB933108A (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2642420B1 (fr) * | 1989-01-27 | 1991-09-06 | Valpan Sa Labo Pharma | Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| WO2007027566A2 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| EP2043627A2 (en) * | 2006-07-05 | 2009-04-08 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
| JP2014051535A (ja) * | 2013-12-19 | 2014-03-20 | Fujifilm Corp | 鉄、カルシウム、又はマグネシウムの吸収を促進する方法 |
| CN113559118B (zh) * | 2021-08-04 | 2022-05-03 | 中国科学院水生生物研究所 | 亚铁离子在防治鲤疱疹病毒Ⅱ型(CyHV2)感染中的应用 |
-
1961
- 1961-01-20 GB GB2470/61A patent/GB933108A/en not_active Expired
- 1961-01-25 BE BE599466A patent/BE599466A/fr unknown
- 1961-01-31 ES ES0264510A patent/ES264510A1/es not_active Expired
- 1961-02-03 FR FR851607A patent/FR904M/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BE599466A (fr) | 1961-05-16 |
| GB933108A (en) | 1963-08-08 |
| FR904M (en:Method) | 1961-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8105292A1 (es) | Procedimiento para la obtencion de derivado de la difenilu- rea halogenosustituidos | |
| GB1078874A (en) | Therapeutic compositions | |
| ES264510A1 (es) | Metodo para la preparaciën de preparados de hierro de elevado poder de absorciën | |
| GB975387A (en) | Multivitamin compositions | |
| ES370058A1 (es) | Procedimiento para la preparacion de composiciones farma- ceuticas efervescentes. | |
| ES364982A1 (es) | Un procedimiento para la elaboracion de un preparado de hierro oral. | |
| GB1210968A (en) | Improvements in or relating to the treatment of gastric ailments | |
| US2519487A (en) | Multivitamin preparation | |
| GB1294299A (en) | Isoniazid derivative | |
| US3655882A (en) | Stable dietary supplement for new born pigs | |
| GB972672A (en) | Pharmaceutical preparations containing compounds of the androstane series | |
| Brise | Effect of surface-active agents on iron absorption | |
| GB1364366A (en) | Derivatives of 4-chloro-5-sulphamoyl-anthranilic acid their preparation and pahamaceutical compositions comprising them | |
| JPS646214A (en) | Remedy for ulcerative colonopathy | |
| GB1352392A (en) | Phenylisopropylamine derivatives | |
| ES377523A1 (es) | Un procedimiento para fabricar una sustancia combinada, compuesta de acido germanico y cisteina. | |
| McLean et al. | STUDIES ON HEPATIC NECROSIS INDUCED BY DIETARY MEANS: V. THE INFLUENCE OF THYROID ACTIVITY ON THE PRODUCTION OF HEPATIC NECROSIS BY DIETARY MEANS | |
| IE38235B1 (en) | Preparations for combatting swine dysentery | |
| GB1422745A (en) | Pharmaceutical compositions containing 4-hydroxy- 1,23-benzotriazine and methods of using same | |
| GB908634A (en) | Pharmaceutical compositions containing pararosaniline or derivatives thereof | |
| GB653026A (en) | Vitamin preparations | |
| GB890638A (en) | Compositions for combating retinitis pigmentosa | |
| IE36780L (en) | Pharmaceutical preparations | |
| GB967133A (en) | Improvements in or relating to anti-tubercular and anti-leprotic pharmaceutical compositions comprising isonicotinoyl hydrazine derivatives | |
| GB1262315A (en) | New benzenesulphonamide derivatives, their production ond compositions containing same |